Genotyping targets individuals at high risk for H. pylori-associated stomach cancer

November 19, 2002

A new study indicates that people carrying certain strains of the Helicobacter pylori bacterium who also have specific genetic polymorphisms are more likely to develop stomach cancer than others. The findings appear in the November 20 issue of the Journal of the National Cancer Institute.

People infected with H. pylori have an increased risk of stomach cancer, but many of these people will never develop the disease. Past studies have suggested that disease progression depends on a number of factors, including the bacterial strain and genetic variations in the host.

To determine whether certain combinations of bacterial and host genotypes increase the risk of stomach cancer, Céu Figueiredo, Ph.D., of the Institute of Molecular Pathology and Immunology at the University of Porto in Portugal, and colleagues examined 221 people with chronic gastritis and 222 people with stomach cancer.

The authors found that certain combinations of bacterial and host genotypes were strongly associated with the risk of stomach cancer. For example, people carrying a high-activity version of interleukin-1 beta gene who were infected by an H. pylori strain with a particular variant of the vacA vacuolating cytotoxin had a nearly 90-fold increase in the risk of stomach cancer.

"Our findings indicate that H. pylori and host genotyping can be important in better defining disease risk and preferentially targeting H. pylori eradication to high-risk individuals," the authors conclude.

In an accompanying editorial, Martin Blaser, M.D., of the New York University School of Medicine, says that these findings are promising, but he cautions that it still too early to generalize from this work.

"The study needs confirmation, different ethnic groups must be examined, the technique must be simplified for general use, and our understanding of the risks and benefits of H. pylori must grow," he writes. "Nevertheless, assessing risk for gastric diseases now is becoming a tractable problem and may ultimately prove to be a paradigm for other microbially induced diseases."
-end-
Contact: Céu Figueiredo or José Carlos Machado, Institute of Molecular Pathology and Immunology at the University of Porto,
35-122-557-0765;
fax: 35-122-557-0799,
ceu.figueiredo@ipatimup.pt or josem@ipatimup.pt

Editorial: Pamela McDonnell, NYU School of Medicine, 212-404-3555, Pam.McDonnell@med.nyu.edu.

Figueiredo C, Machado J, Pharoah P, Seruca R, Sousa S, Carvalho R, et al. Helicobacter pylori and interleukin 1 genotyping: An opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 2002;94:1680-7.

Editorial: Blaser M. Polymorphic bacteria persisting in polymorphic hosts: Assessing helicobacter pylori-related risks for gastric cancer. J Natl Cancer Inst 2002;94:1662-3.

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage.

Journal of the National Cancer Institute

Related Stomach Cancer Articles from Brightsurf:

Immunotherapy may work better in stomach cancer when combined with chemo, given earlier
Immunotherapy, often ineffective against stomach cancer, was more effective when combined with chemotherapy and given earlier, finds a new study in mice.

UArizona Health Sciences researchers find biomarker that can appear before stomach cancer
A microRNA that can be found in a blood sample may make it easier to detect gastric cancer and could lead to improved treatment for the disease and others like it that are resistant to common immunotherapies.

Study gauges specific site stomach cancer risks among ethnic groups
Non-white Americans, especially Asian Americans, are at disproportionately higher risk for gastric cancer compared to non-Hispanic white Americans.

Epstein-Barr virus rewires host epigenomes to drive stomach cancer
Researchers in Japan and Singapore have discovered a molecular mechanism that explains how Epstein-Barr virus (EBV) infection alters a host's epigenome to promote tumorigenesis (the transformation of normal cells into cancer cells) in certain types of stomach cancer.

MIPT bioinformaticians find way to personalize drug prescription against stomach cancer
Researchers from the Moscow Institute of Physics and Technology and their colleagues have developed the first technique for personalizing stomach cancer therapy based on RNA sequencing of tumor cells.

Scientists discover how a curvy, stomach cancer-causing bacterium maintains its shape
A new study published in eLife shows how a common stomach bacterium is able to keep its corkscrew-like shape as it grows.

A molecular switch for stomach disease
A research team from Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) has revealed a new mechanism which controls the causes of infection with H. pylori, triggering the development of stomach diseases.

Many younger patients with stomach cancer have a distinct disease, Mayo research discovers
Many people under 60 who develop stomach cancer have a 'genetically and clinically distinct' disease, new Mayo Clinic research has discovered.

Common stomach bacteria is attracted to bleach
The widespread stomach pathogen Helicobacter pylori is attracted to bleach, according to new research by Arden Perkins of the University of Oregon in Eugene, Oregon, and colleagues.

Scientists discover origin of cell mask that hides stomach cancer
In a recent study, researchers from Hiroshima University have uncovered the origin of a layer of cells that look like normal stomach lining on top of sites of stomach cancer: it is produced by the cancer tissue itself.

Read More: Stomach Cancer News and Stomach Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.